Measurement of C-terminal telopeptide of type I collagen (CTX) in serum

Clinical Biochemistry

Volumn 45, Issue 12, 2012, Pages 928-935

  Chubb, S A Paul ^a,b  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b PATHWEST LABORATORY MEDICINE   (Australia)

Author keywords

Bone resorption; Collagen C telopeptide; Collagen peptides; CrossLaps ; CTX; Osteoporosis; Serum

Indexed keywords

CARBOXY TERMINAL TELOPEPTIDE; COLLAGEN TYPE 1;

BONE TURNOVER; CIRCADIAN RHYTHM; DIET RESTRICTION; ENZYME LINKED IMMUNOSORBENT ASSAY; EXERCISE; FRACTURE; GROWTH RATE; HUMAN; OSTEOLYSIS; PREMENOPAUSE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; RADIOIMMUNOASSAY; REVIEW; URINALYSIS;

BIOLOGICAL MARKERS; BLOOD CHEMICAL ANALYSIS; BONE RESORPTION; CIRCADIAN RHYTHM; COLLAGEN TYPE I; EXERCISE; FASTING; HUMANS; OSTEOPOROSIS; PEPTIDES; REFERENCE VALUES;

EID: 84863876569     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2012.03.035     Document Type: Review

References (68)

1. Vasikaran S., Eastell R., Bruyere O., Foldes A.J., Garnero P., Griesmacher A., et al. Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos Int 2011, 22(2):391-420.
2. Bonde M., Qvist P., Fledelius C., Riis B.J., Christiansen C. Immunoassay for quantifying type I collagen degradation products in urine evaluated. Clin Chem 1994, 40(11):2022-2025.
3. Bonde M., Fledelius C., Qvist P., Christiansen C. Coated-tube radioimmunoassay for C-telopeptides of type I collagen to assess bone resorption. Clin Chem 1996, 42(10):1639-1644.
4. Fledelius C., Kolding I., Qvist P., Bonde M., Hassager C., Reginster J.Y., et al. Development of a monoclonal antibody to urinary degradation products from the C-terminal telopeptide alpha 1 chain of type I collagen. Application in an enzyme immunoassay and comparison to CrossLaps ELISA. Scand J Clin Lab Invest 1997, 57(1):73-83.
5. Fledelius C., Johnsen A.H., Cloos P.A., Bonde M., Qvist P. Characterization of urinary degradation products derived from type I collagen. Identification of a beta-isomerized Asp-Gly sequence within the C-terminal telopeptide (alpha1) region. J Biol Chem 1997, 272(15):9755-9763.
6. Cloos P.A., Fledelius C. Collagen fragments in urine derived from bone resorption are highly racemized and isomerized: a biological clock of protein aging with clinical potential. Biochem J 2000, 345(3):473-480.
7. Garnero P., Cloos P., Sornay-Rendu E., Qvist P., Delmas P.D. Type I collagen racemization and isomerization and the risk of fracture in postmenopausal women: the OFELY prospective study. J Bone Miner Res 2002, 17(5):826-833.
8. Bonde M., Garnero P., Fledelius C., Qvist P., Delmas P.D., Christiansen C. Measurement of bone degradation products in serum using antibodies reactive with an isomerized form of an 8 amino acid sequence of the C-telopeptide of type I collagen. J Bone Miner Res 1997, 12(7):1028-1034.
9. Rosenquist C., Fledelius C., Christgau S., Pedersen B.J., Bonde M., Qvist P., et al. Serum CrossLaps One Step ELISA. First application of monoclonal antibodies for measurement in serum of bone-related degradation products from C-terminal telopeptides of type I collagen. Clin Chem 1998, 44(11):2281-2289.
10. Crofton P.M., Evans N., Taylor M.R., Holland C.V. Serum CrossLaps: pediatric reference intervals from birth to 19years of age. Clin Chem 2002, 48(4):671-673.
11. Garnero P., Borel O., Delmas P.D. Evaluation of a fully automated serum assay for C-terminal cross-linking telopeptide of type I collagen in osteoporosis. Clin Chem 2001, 47(4):694-702.
12. Okabe R., Nakatsuka K., Inaba M., Miki T., Naka H., Masaki H., et al. Clinical evaluation of the Elecsys beta-CrossLaps serum assay, a new assay for degradation products of type I collagen C-telopeptides. Clin Chem 2001, 47(8):1410-1414.
13. Claudon A., Vergnaud P., Valverde C., Mayr A., Klause U., Garnero P. New automated multiplex assay for bone turnover markers in osteoporosis. Clin Chem 2008, 54(9):1554-1563.
14. Eastell R., Garnero P., Audebert C., Cahall D.L. Reference intervals of bone turnover markers in healthy premenopausal women: results from a cross-sectional European study. Bone 2012, 10.1016/j.bone.2012.02.003.
15. Stokes F.J., Ivanov P., Bailey L.M., Fraser W.D. The effects of sampling procedures and storage conditions on short-term stability of blood-based biochemical markers of bone metabolism. Clin Chem 2011, 57(1):138-140.
16. Schlemmer A., Hassager C. Acute fasting diminishes the circadian rhythm of biochemical markers of bone resorption. Eur J Endocrinol 1999, 140(4):332-337.
17. Aoshima H., Kushida K., Takahashi M., Ohishi T., Hoshino H., Suzuki M., et al. Circadian variation of urinary type I collagen crosslinked C-telopeptide and free and peptide-bound forms of pyridinium crosslinks. Bone 1998, 22(1):73-78.
18. Wichers M., Schmidt E., Bidlingmaier F., Klingmuller D. Diurnal rhythm of CrossLaps in human serum. Clin Chem 1999, 45(10):1858-1860.
19. Christgau S., Bitsch-Jensen O., Hanover Bjarnason N., Gamwell Henriksen E., Qvist P., Alexandersen P., et al. Serum CrossLaps for monitoring the response in individuals undergoing antiresorptive therapy. Bone 2000, 26(5):505-511.
20. Qvist P., Christgau S., Pedersen B.J., Schlemmer A., Christiansen C. Circadian variation in the serum concentration of C-terminal telopeptide of type I collagen (serum CTx): effects of gender, age, menopausal status, posture, daylight, serum cortisol, and fasting. Bone 2002, 31(1):57-61.
21. Clowes J.A., Hannon R.A., Yap T.S., Hoyle N.R., Blumsohn A., Eastell R. Effect of feeding on bone turnover markers and its impact on biological variability of measurements. Bone 2002, 30(6):886-890.
22. Gass M.L., Kagan R., Kohles J.D., Martens M.G. Bone turnover marker profile in relation to the menstrual cycle of premenopausal healthy women. Menopause 2008, 15(4):667-675.
23. Rosen H.N., Moses A.C., Garber J., Iloputaife I.D., Ross D.S., Lee S.L., et al. Serum CTX: a new marker of bone resorption that shows treatment effect more often than other markers because of low coefficient of variability and large changes with bisphosphonate therapy. Calcif Tissue Int 2000, 66(2):100-103.
24. Rogers A., Glover S.J., Eastell R. A randomised, double-blinded, placebo-controlled, trial to determine the individual response in bone turnover markers to lasofoxifene therapy. Bone 2009, 45(6):1044-1052.
25. Alvarez L., Ricos C., Peris P., Guanabens N., Monegal A., Pons F., et al. Components of biological variation of biochemical markers of bone turnover in Paget's bone disease. Bone 2000, 26(6):571-576.
26. Pasco J.A., Henry M.J., Kotowicz M.A., Sanders K.M., Seeman E., Pasco J.R., et al. Seasonal periodicity of serum vitamin D and parathyroid hormone, bone resorption, and fractures: the Geelong osteoporosis study. J Bone Miner Res 2004, 19(5):752-758.
27. Storm D., Eslin R., Porter E.S., Musgrave K., Vereault D., Patton C., et al. Calcium supplementation prevents seasonal bone loss and changes in biochemical markers of bone turnover in elderly New England women: a randomized placebo-controlled trial. J Clin Endocrinol Metab 1998, 83(11):3817-3825.
28. Woitge H.W., Scheidt-Nave C., Kissling C., Leidig-Bruckner G., Meyer K., Grauer A., et al. Seasonal variation of biochemical indexes of bone turnover: results of a population-based study. J Clin Endocrinol Metab 1998, 83(1):68-75.
29. Blumsohn A., Naylor K.E., Timm W., Eagleton A.C., Hannon R.A., Eastell R. Absence of marked seasonal change in bone turnover: a longitudinal and multicenter cross-sectional study. J Bone Miner Res 2003, 18(7):1274-1281.
30. Jenkins N., Black M., Schneider H.G., Paul E., Pasco J. Age related reference ranges for serum procollagen type I N-terminal propeptide (P1NP) and type I collagen C-telopeptide (CTX) in the Australian male population. Clin Biochem Rev 2010, 31(Suppl. (i)):S29-S30.
31. Bjarnason N.H., Henriksen E.E., Alexandersen P., Christgau S., Henriksen D.B., Christiansen C. Mechanism of circadian variation in bone resorption. Bone 2002, 30(1):307-313.
32. Henriksen D.B., Alexandersen P., Bjarnason N.H., Vilsboll T., Hartmann B., Henriksen E.E., et al. Role of gastrointestinal hormones in postprandial reduction of bone resorption. J Bone Miner Res 2003, 18(12):2180-2189.
33. Henriksen D.B., Alexandersen P., Hartmann B., Adrian C.L., Byrjalsen I., Bone H.G., et al. Disassociation of bone resorption and formation by GLP-2: a 14-day study in healthy postmenopausal women. Bone 2007, 40(3):723-729.
34. Henriksen D.B., Alexandersen P., Hartmann B., Adrian C.L., Byrjalsen I., Bone H.G., et al. Four-month treatment with GLP-2 significantly increases hip BMD: a randomized, placebo-controlled, dose-ranging study in postmenopausal women with low BMD. Bone 2009, 45(5):833-842.
35. Luchavova M., Zikan V., Michalska D., Raska I., Kubena A.A., Stepan J.J. The effect of timing of teriparatide treatment on the circadian rhythm of bone turnover in postmenopausal osteoporosis. Eur J Endocrinol 2011, 164(4):643-648.
36. Scott J.P., Sale C., Greeves J.P., Casey A., Dutton J., Fraser W.D. The effect of training status on the metabolic response of bone to an acute bout of exhaustive treadmill running. J Clin Endocrinol Metab 2010, 95(8):3918-3925.
37. Scott J.P., Sale C., Greeves J.P., Casey A., Dutton J., Fraser W.D. The role of exercise intensity in the bone metabolic response to an acute bout of weight-bearing exercise. J Appl Physiol 2011, 110(2):423-432.
38. Herrmann M., Muller M., Scharhag J., Sand-Hill M., Kindermann W., Herrmann W. The effect of endurance exercise-induced lactacidosis on biochemical markers of bone turnover. Clin Chem Lab Med 2007, 45(10):1381-1389.
39. Maimoun L., Manetta J., Couret I., Dupuy A.M., Mariano-Goulart D., Micallef J.P., et al. The intensity level of physical exercise and the bone metabolism response. Int J Sports Med 2006, 27(2):105-111.
40. Maimoun L., Simar D., Malatesta D., Caillaud C., Peruchon E., Couret I., et al. Response of bone metabolism related hormones to a single session of strenuous exercise in active elderly subjects. Br J Sports Med 2005, 39(8):497-502.
41. Adami S., Gatti D., Viapiana O., Fiore C.E., Nuti R., Luisetto G., et al. Physical activity and bone turnover markers: a cross-sectional and a longitudinal study. Calcif Tissue Int 2008, 83(6):388-392.
42. Eastell R., Barton I., Hannon R.A., Chines A., Garnero P., Delmas P.D. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res 2003, 18(6):1051-1056.
43. de Papp A.E., Bone H.G., Caulfield M.P., Kagan R., Buinewicz A., Chen E., et al. A cross-sectional study of bone turnover markers in healthy premenopausal women. Bone 2007, 40(5):1222-1230.
44. Glover S.J., Gall M., Schoenborn-Kellenberger O., Wagener M., Garnero P., Boonen S., et al. Establishing a reference interval for bone turnover markers in 637 healthy, young, premenopausal women from the United Kingdom, France, Belgium, and the United States. J Bone Miner Res 2009, 24(3):389-397.
45. Glover S.J., Garnero P., Naylor K., Rogers A., Eastell R. Establishing a reference range for bone turnover markers in young, healthy women. Bone 2008, 42(4):623-630.
46. Adami S., Bianchi G., Brandi M.L., Giannini S., Ortolani S., DiMunno O., et al. Determinants of bone turnover markers in healthy premenopausal women. Calcif Tissue Int 2008, 82(5):341-347.
47. Ardawi M.S., Maimani A.A., Bahksh T.A., Rouzi A.A., Qari M.H., Raddadi R.M. Reference intervals of biochemical bone turnover markers for Saudi Arabian women: a cross-sectional study. Bone 2010, 47(4):804-814.
48. Olmos J.M., Hernandez J.L., Martinez J., Pariente E., Llorca J., Gonzalez-Macias J. Bone turnover markers in Spanish adult men: the camargo cohort study. Clin Chim Acta 2010, 411(19-20):1511-1515.
49. Alberti C., Chevenne D., Mercat I., Josserand E., Armoogum-Boizeau P., Tichet J., et al. Serum concentrations of insulin-like growth factor (IGF)-1 and IGF binding protein-3 (IGFBP-3), IGF-1/IGFBP-3 ratio, and markers of bone turnover: reference values for French children and adolescents and z-score comparability with other references. Clin Chem 2011, 57(10):1424-1435.
50. Huang Y., Eapen E., Steele S., Grey V. Establishment of reference intervals for bone markers in children and adolescents. Clin Biochem 2011, 44(10-11):771-778.
51. Rauchenzauner M., Schmid A., Heinz-Erian P., Kapelari K., Falkensammer G., Griesmacher A., et al. Sex- and age-specific reference curves for serum markers of bone turnover in healthy children from 2months to 18years. J Clin Endocrinol Metab 2007, 92(2):443-449.
52. Herrmann M., Herrmann W. The assessment of bone metabolism in female elite endurance athletes by biochemical bone markers. Clin Chem Lab Med 2004, 42(12):1384-1389.
53. Moghaddam A., Muller U., Roth H.J., Wentzensen A., Grutzner P.A., Zimmermann G. TRACP 5b and CTX as osteological markers of delayed fracture healing. Injury 2011, 42(8):758-764.
54. Uebelhart D., Gineyts E., Chapuy M.C., Delmas P.D. Urinary excretion of pyridinium crosslinks: a new marker of bone resorption in metabolic bone disease. Bone Miner 1990, 8(1):87-96.
55. McClung M.R., Lewiecki E.M., Cohen S.B., Bolognese M.A., Woodson G.C., Moffett A.H., et al. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 2006, 354(8):821-831.
56. Saag K., Lindsay R., Kriegman A., Beamer E., Zhou W. A single zoledronic acid infusion reduces bone resorption markers more rapidly than weekly oral alendronate in postmenopausal women with low bone mineral density. Bone 2007, 40(5):1238-1243.
57. Bauer D.C., Garnero P., Harrison S.L., Cauley J.A., Eastell R., Ensrud K.E., et al. Biochemical markers of bone turnover, hip bone loss, and fracture in older men: the MrOS study. J Bone Miner Res 2009, 24(12):2032-2038.
58. Chapurlat R.D., Garnero P., Breart G., Meunier P.J., Delmas P.D. Serum type I collagen breakdown product (serum CTX) predicts hip fracture risk in elderly women: the EPIDOS study. Bone 2000, 27(2):283-286.
59. Garnero P., Sornay-Rendu E., Claustrat B., Delmas P.D. Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY study. J Bone Miner Res 2000, 15(8):1526-1536.
60. Gerdhem P., Ivaska K.K., Alatalo S.L., Halleen J.M., Hellman J., Isaksson A., et al. Biochemical markers of bone metabolism and prediction of fracture in elderly women. J Bone Miner Res 2004, 19(3):386-393.
61. Ivaska K.K., Gerdhem P., Vaananen H.K., Akesson K., Obrant K.J. Bone turnover markers and prediction of fracture: a prospective follow-up study of 1040 elderly women for a mean of 9 years. J Bone Miner Res 2010, 25(2):393-403.
62. Meier C., Nguyen T.V., Center J.R., Seibel M.J., Eisman J.A. Bone resorption and osteoporotic fractures in elderly men: the Dubbo osteoporosis epidemiology study. J Bone Miner Res 2005, 20(4):579-587.
63. Dobnig H., Piswanger-Solkner J.C., Obermayer-Pietsch B., Tiran A., Strele A., Maier E., et al. Hip and nonvertebral fracture prediction in nursing home patients: role of bone ultrasound and bone marker measurements. J Clin Endocrinol Metab 2007, 92(5):1678-1686.
64. Szulc P., Montella A., Delmas P.D. High bone turnover is associated with accelerated bone loss but not with increased fracture risk in men aged 50 and over: the prospective MINOS study. Ann Rheum Dis 2008, 67(9):1249-1255.
65. Bauer D.C. Biochemical markers of bone turnover: the study of osteoporotic fracture. Bone markers - biochemical and clinical perspectives 2001, 219-223. Martin Dunitz Ltd., London. R. Eastell, M. Baumann, N. Hoyle, L. Wieczorek (Eds.).
66. Bauer D.C., Black D.M., Garnero P., Hochberg M., Ott S., Orloff J., et al. Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial. J Bone Miner Res 2004, 19(8):1250-1258.
67. Szulc P. The role of bone turnover markers in monitoring treatment in postmenopausal osteoporosis. Clin Biochem 2012, 10.1016/j.clinbiochem.2012.01.022.
68. Szulc P., Garnero P., Munoz F., Marchand F., Delmas P.D. Cross-sectional evaluation of bone metabolism in men. J Bone Miner Res 2001, 16(9):1642-1650.